A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam.
Few data address the outcomes of patients who have multidrug-resistant tuberculosis (MDR-TB), defined as resistance to at least isoniazid and rifampin, and who receive a standard World Health Organization (WHO) recommended retreatment regimen after relapse or failure with initial treatment. In this case series, we examined treatment outcomes of a convenience sample of 42 relapse or failure patients who had documented MDR-TB and who had received a standard WHO retreatment regimen (2SHRZE/1HRZE/5H3R3E3). One patient died of tuberculosis in the last month of treatment; the remaining 41 patients completed retreatment. Of the 42, 14 (33%) were sputum smear-negative on completion of therapy. The proportion of patients cured of MDR-TB with the WHO retreatment regimen was similar to historic outcomes when no chemotherapy for TB was given.
Lan NTN
Pham Ngoc Thach Tuberculosis and Lung Diseases Center, Ho Chi Minh City, Vietnam.
Lademarco
M F
MF
Binkin
N J
NJ
Tung
L B
LB
Quy
H T
HT
Cĵ
N V
NV
D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000592:standards* / Q000627:therapeutic use*; D002985:Clinical Protocols / Q000592:standards*; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000592:standards* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D019233:Retreatment; D012293:Rifampin / Q000592:standards* / Q000627:therapeutic use*; D017211:Treatment Failure; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000401:mortality*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000401:mortality*; D014744:Vietnam; D014944:World Health Organization
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin